Non-invasive and automated treatments of heart arrhythmias
EBAMed SA
Incorporated
08.10.2018Headquarters
GenevaSupport
Today, heart arrhythmias are treated with an invasive manual surgery requiring several hours intervention via catheter from specialized staff and large costs. EBAMed's solution combines medical devices for proton therapy and motion tracking imaging and software to enable the treatment of patients in a non-invasive way, in a single out-patient session, whilst increasing 5-fold the patient throughput and saving costs.
News
EBAMed secures EUR 1.6M, concluding Series A Round at EUR 16M (venturelab.swiss)
EBAMed completes Series A with EUR 1.6M investment (startupticker.ch)
New FONGIT Innovation Initiation Program launched (startupticker.ch)
EUR 14.35 million to advance cardiac radiation ablation therapy (startupticker.ch)
EBAMed raises EUR 14.35 million in series A funding for non-invasive ventricular tachycardia treatment (venturelab.swiss)
The 16 most promising medtech startups in 2022, according to investors (TOP 100)
FIF funding supports three women led deeptech startups (startupticker.ch)
First Patient enrolled in EBAMed Prospective Imaging Study (startupticker.ch)
Female leaders at the top (startupticker.ch)
More EU funds for Swiss start-up projects (startupticker.ch)
Milestones news
• Development of deep-learning algorithms to monitor and react to cardiac movement during cardiac radio therapy • System prototype • Completion of feasibility studies, including animal testing
Videos and Presentations
Startup Champions Seed Night 2018